Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Net Cash Flow (2022 - 2025)

Gossamer Bio's Net Cash Flow history spans 4 years, with the latest figure at $28.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 62.37% year-over-year to $28.8 million; the TTM value through Dec 2025 reached -$8.5 million, down 160.3%, while the annual FY2025 figure was -$8.5 million, 160.3% down from the prior year.
  • Net Cash Flow reached $28.8 million in Q4 2025 per GOSS's latest filing, up from -$17.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $59.6 million in Q3 2022 to a low of -$58.5 million in Q3 2024.
  • Average Net Cash Flow over 4 years is -$9.1 million, with a median of -$17.2 million recorded in 2025.
  • Peak YoY movement for Net Cash Flow: skyrocketed 270.18% in 2024, then crashed 351.73% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at -$42.1 million in 2022, then dropped by 20.3% to -$50.7 million in 2023, then soared by 134.99% to $17.7 million in 2024, then soared by 62.37% to $28.8 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Net Cash Flow are $28.8 million (Q4 2025), -$17.3 million (Q3 2025), and -$2.8 million (Q2 2025).